# US 2006/0153843 A1 · Method of immunomodulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153843 A1
- Document ID: US20060153843A1
- Status: Published application
- Kind: A1
- Application number: 10/524,716
- Filed: 2003-08-15
- Published: 2006-07-13
- Earliest claimed: 2002-08-15
- Assignees: The Corporation of The Trustees of The Sisters of Mercy in Queensland of South Brisbane
- Inventors: Masato Kato; David Munster; Derek Hart
- Web page: https://patentgrep.com/patent/US20060153843A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates generally to a method for modulating the activity of cells of the immune system, including stimulator and responder cells and to agents useful therefor. More particularly, the present invention relates to a method for preventing or down-regulating one or more functional activities of stimulator and responder cells such as, respectively, antigen-presenting cells and lymphocytes inter alia. The present invention further provides antibodies, which interact specifically with epitopes present on the surface of antigen-presenting cells and lymphocytes, resulting in depletion, down-regulation or destruction of targeted antigen-presenting cells and lymphocytes in vivo or in vitro. The instant invention further provides a method for modulating an immune response in a subject and, in particular, for down-regulating the immuno-activity of an allogeneic immuno-competent graft and/or the immune response of a recipient of a solid organ transplant. The ability to modulate stimulator and responder cell immuno-activity may be useful, inter alia, in a range of immuno-therapeutic and immuno-prophylactic treatments that benefit from immune suppression.

## Claims

### Claim 1

A method for modulating immuno-activity of a cell selected from a stimulator myeloid dendritic cell (DC) and a responder CD4+CD8− T cell or CD4−CD8+ T cell said method comprising contacting said cell with an effective amount of an antibody or antigen-binding fragment thereof which couples, binds or otherwise associates with CD83 and in turn prevents, inhibits or otherwise down-regulates one or more functional activities of said cell by inducing cell lysis.

### Claim 2 (depends on 1)

The method of claim 1 wherein the antibody is a monoclonal antibody or a functional equivalent thereof.

### Claim 3 (depends on 1)

The method of claim 1 wherein the cell is mammalian derived.

### Claim 4 (depends on 3)

The method of claim 3 wherein the mammalian cell is a human cell.

### Claim 5 (depends on 2)

The method of claim 2 wherein the functional equivalent is an antigen-binding derivative, fragment, homolog, analog or chemical equivalent of the antibody.

### Claim 6 (depends on 1)

The method of claim 1 wherein lysis is caused by antibody-dependent cell-mediated cytotoxicity.

### Claim 7 (depends on 2)

The method of claim 2 wherein the antibody in conjugated with a toxic component which induces or otherwise facilitates lysis of the APC and/or lymphocyte.

### Claim 8

A method for modulating the immuno-activity of a myeloid DC and/or T cell, said method comprising contacting said DC and/or T cell with an effective amount of a monoclonal antibody specific for CD83 for a time and under conditions sufficient to prevent, inhibit or otherwise down-regulate one or more of antigen endocytosis, antigen processing and/or antigen presentation by said DC and activation of macrophages, stimulation of antibody production, and/or killing of target cells by said T cell.

### Claim 9

A method for modulating an immune response in a subject, said method comprising administering to said subject an effective amount of an antibody which couples, binds or otherwise associates with a myeloid DC's and/or T cell's surface activation molecule for a time and under conditions sufficient to induce cell lysis of said DC and/or T cell.

### Claim 10

A method for down-regulating the immuno-activity of an immuno-competent graft, said method comprising administering to said subject an effective amount of an antibody which couples, binds or otherwise associates with a myeloid DC's and/or a T cell's CD83 molecule, for a time and under conditions sufficient to induce cell lysis of said DC and/or a T cell.

### Claim 11

A method for down-regulating the immuno-activity of a bone marrow graft in a subject, said method comprising administering to said subject an effective amount of monoclonal antibody against CD83, for a time and under conditions sufficient to prevent, inhibit or otherwise down-regulate one or more functional activities of a DC and/or T-cell by inducing cell lysis.

### Claim 12

A method for the prophylactic and/or therapeutic treatment of a condition characterized by the aberrant, unwanted or otherwise inappropriate immuno-activity of an immuno-competent graft, said method comprising contacting said graft with an effective amount of an antibody or a derivative, homolog, analog, chemical equivalent or mimetic thereof, which couples, binds or otherwise associates with a myeloid DC's and/or a T cell's surface activation CD83 molecule, for a time and under conditions sufficient to prevent, inhibit or otherwise down-regulate the immuno-activity of said DC and/or T cell by inducing cell lysis.

### Claim 13 (depends on 17)

The method of claim 17 wherein the immuno-competent graft comprises allogenic bone marrow cells.

### Claim 14 (depends on 12)

The method of claim 12 wherein the lymphocyte is a CD4+ CD8− or CD4− CD8+ T cell.

### Claim 15

A method for the prophylactic and/or therapeutic treatment of a condition characterized by the aberrant, unwanted or otherwise inappropriate immuno-activity of an immuno-competent graft in a subject, said method comprising contacting said graft with an effective amount of an antibody or a derivative, homolog, analog, chemical equivalent or mimetic thereof, which couples, binds or otherwise associates with a myeloid DC's and/or a T cell's CD83 molecule derived from said graft, for a time and under conditions sufficient to prevent, inhibit or otherwise down-regulate the said inappropriate immuno-activity of said graft by inducing cell lysis.

### Claim 16 (depends on 15)

The method of claim 15 wherein the subject is a mammal.

### Claim 17 (depends on 16)

The method of claim 16 wherein the mammal is a human.

### Claim 18 (depends on 15)

The method of claim 15 wherein the condition is graft versus host disease.

### Claim 19 (depends on 15)

The method of claim 15 wherein the graft is an allergenic bone marrow graft, spleen cell graft or stem cell graft.

### Claim 20

A method for the prophylactic and/or therapeutic treatment of a condition characterized by an aberrant, unwanted or otherwise inappropriate immune response in a subject, said method comprising administering to said subject an effective amount of an antibody or antigen-binding fragment thereof which couples, binds or otherwise associates with CD83 on the surface of a myeloid DC's and/or a CD4+CD8− T cell or CD4−CD8+ T cell, for a time and under conditions sufficient to prevent, inhibit or otherwise down-regulate the immuno-activity of said DC and/or T cell by inducing cell lysis.
